Abstract Body

HIV-1 entry depends on the interaction of the envelope (Env) protein’s variable loop 3 (V3) with a co-receptor. While this indispensable function renders the V3 a key target for inhibition, the vigorous antibody response elicited in natural infection is largely non-neutralizing owing to conformational masking of the V3 crown on the prefusion-closed Env trimer. Only a fraction of individuals develops broadly neutralizing antibodies (bnAbs) targeting the V3 base on a closed Env. In the CD4-bound conformation, the V3 becomes fully accessible and conformationally dynamic. Functional relevance of these intermediate V3 conformations and their potential for broad neutralization still remain to be resolved.

Here we applied the Designed Ankyrin Repeat Protein (DARPIn) technology to select DARPins targeting HIV-1 Env by Ribosome Display. Hits were screened for V3 binders with broad neutralizing capacity. Neutralization breadth was assessed on a 42-multiclade Tier-2 virus panel in the TZM-bl assay. DARPin epitopes were characterized by binding to Env derivatives, deep mutational Env scanning, X-ray crystallography, cryo-EM and molecular dynamics.

We identified 8 distinct V3 specific DARPins with exceptional neutralization breadth of up to 93%. Unlike V3-glycan bnAbs, these broadly neutralizing DARPins (bnDs) bound V3 solely on open but not closed Env. X-ray and cryo-EM structure analyses of bnD.8 and bnD.9 revealed binding to a 3-turn amphipathic alpha-helix in the C-Strand of V3 spanning residues 314 to 324. We termed this novel conformation ?V3C. Remarkably, the ?V3C helix was trapped by two unrelated bnDs and observed both in complex with V3 peptide and open, CD4-triggered Env trimer. Molecular dynamics simulations indicated that the ?V3C helix remains stable in the absence of the bnDs, emphasizing a functional relevance. Comprehensive Env mutation scanning underlined functional importance. Escape mutations accumulated on the contact face of the helix, but no enrichment of putative helix disturbing mutations occurred.

The discovery of post-CD4 engagement acting V3 inhibitors with extraordinary breadth is remarkable. The helical V3 conformation they define sheds light on V3 conformational dynamics after CD4 engagement and reveals a new site of vulnerability on HIV-1 Env. Our findings emphasize the importance of V3 and the open Env conformation as a target for inhibitors and mark the newly defined ?V3C helix as a blueprint for epitope-based vaccine design.